CORAT Therapeutics GmbH receives € 38.7 Mio. funding for the clinical development of COR-101, a drug to treat hospitalized COVID-19 patients with moderate to severe symptomsClinical processing of COR-101 is financially securedPreparation for market entry in 2023...
